Congresses and Publications

SEQUOIA 5-year follow-up (arm C): zanubrutinib in patients with del(17p) and treatment-naïve CLL/SLL

SEQUOIA 5-year follow-up (arm C): zanubrutinib in patients with del(17p) and treatment-naïve CLL/SLL Zanubrutinib vs venetoclax+obinutuzumab in treatment-naive (TN) chronic lymphocytic leukemia (CLL)

A first-in-human, phase 1 study of BGB-15025 (hematopoietic progenitor kinase 1 inhibitor) as monotherapy and in combination with tislelizumab (anti-PD-1 antibody) in patients with advanced solid tumors First-in-human, phase 1 study of BGB-26808 (hematopoietic progenitor kinase 1 inhibitor) ± tislelizumab (anti-PD-1) in advanced solid tumors First-line tislelizumab + chemotherapy (CT) vs placebo + CT in extensive-stage small cell lung cancer: long-term follow-up of RATIONALE-312 Tislelizumab plus chemotherapy for first-line advanced or metastatic squamous non-small cell lung cancer: Long-term overall survival subgroup analysis of RATIONALE-307 Tislelizumab treatment beyond progression in advanced sq-NSCLC after 1l chemoimmunotherapy: Results from randomized, phase III RATIONALE-307 study Tislelizumab with or without capecitabine continuation in gastric or gastro-oesophageal junction cancer: RATIONALE-305 post hoc analysis

Direct medical costs of nasopharyngeal carcinoma in Indonesia: a healthcare payer perspective

Direct medical costs of nasopharyngeal carcinoma in Indonesia: a healthcare payer perspective

Updated interim results of sonrotoclax + dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma (R/R MM): an all-oral treatment

Updated interim results of sonrotoclax + dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma (R/R MM): an all-oral treatment

A meta-analysis investigating response rates of continuous bruton tyrosine kinase inhibitor monotherapies in the treatment of B-cell lymphomas A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve (TN) chronic lymphocytic leukemia (CLL) A qualitative study to explore the patient experience of continuous covalent bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: study methodology Combination of zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: results in SEQUOIA arm D Comparative efficacy of zanubrutinib (ZANU) versus fixed-duration acalabrutinib plus venetoclax (AV) for first-line treatment of chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Efficacy and safety of zanubrutinib in a fit subgroup of patients with treatment-naive chronic lymphocytic leukemia: post hoc analyses from the SEQUOIA study Estimating the cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia Number needed to treat analyses of zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia Outcomes, inequities, and access to front-line preferred therapies for chronic lymphocytic leukemia in the United States: a real-world evidence study Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared-decision making Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line (1L) bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL): age-related disparity Risk of second primary malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving first-line therapy: a real-world study SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma Safety and efficacy of zanubrutinib in a subgroup of older patients (≥75 Years) with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma from the SEQUOIA study Updated efficacy and safety of the bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the ongoing phase 1 CaDAnCe-101 study Updated results from the phase 1 study of sonrotoclax (BGB-11417), a novel B-cell lymphoma 2 inhibitor, in combination with zanubrutinib for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma demonstrate deep and durable responses

A meta-analysis investigating response rates of continuous bruton tyrosine kinase inhibitor monotherapies in the treatment of B-cell lymphomas A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve (TN) chronic lymphocytic leukemia (CLL) A qualitative study to explore the patient experience of continuous covalent bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: study methodology Combination of zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: results in SEQUOIA arm D Comparative efficacy of zanubrutinib (ZANU) versus fixed-duration acalabrutinib plus venetoclax (AV) for first-line treatment of chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Efficacy and safety of zanubrutinib in a fit subgroup of patients with treatment-naive chronic lymphocytic leukemia: post hoc analyses from the SEQUOIA study Estimating the cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia Number needed to treat analyses of zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia Outcomes, inequities, and access to front-line preferred therapies for chronic lymphocytic leukemia in the United States: a real-world evidence study Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared-decision making Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line (1L) bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL): age-related disparity Risk of second primary malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving first-line therapy: a real-world study SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma Safety and efficacy of zanubrutinib in a subgroup of older patients (≥75 Years) with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma from the SEQUOIA study Updated efficacy and safety of the bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the ongoing phase 1 CaDAnCe-101 study Updated results from the phase 1 study of sonrotoclax (BGB-11417), a novel B-cell lymphoma 2 inhibitor, in combination with zanubrutinib for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma demonstrate deep and durable responses

Final analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Preliminary safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory b-cell malignancies: Results from CaDAnCe (BGB-16673-102) Sonrotoclax monotherapy for treatment of patients with relapsed/refractory CLL: data from an ongoing phase 1/1b study (BGB-11417-101) Updated efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory CLL/SLL: Results from the ongoing phase 1 CaDAnCe-101 study Updated results from the phase 1 study of sonrotoclax (BGB-11417), a novel BCL2 inhibitor, in combination with zanubrutinib for relapsed/refractory CLL/SLL demonstrate deep and durable responses

Adverse events of interest with zanubrutinib vs fixed-duration combination of venetoclax + obinutuzumab in treatment-naive chronic lymphocytic leukemia Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naive CLL: A matching-adjusted indirect comparison SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Adverse events of interest with zanubrutinib vs fixed-duration combination of venetoclax + obinutuzumab in treatment-naive chronic lymphocytic leukemia BGB-11417-302, a phase 3, randomized, double-blind study of sonrotoclax (BGB-11417) + zanubrutinib vs placebo + zanubrutinib in patients with relapsed or refractory mantle cell lymphoma Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naive CLL: A matching-adjusted indirect comparison Final analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Preliminary safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory b-cell malignancies: Results from BGB-16673-102 Primary analysis results of novel BCL2 inhibitor sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory b-cell malignancies SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Safety data from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma Sonrotoclax monotherapy for treatment of patients with relapsed/refractory CLL: data from an ongoing phase 1/1b study (BGB-11417-101) Updated efficacy & safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia: ongoing phase 1 CaDAnCe-101 study results Updated efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory CLL/SLL: Results from the ongoing phase 1 CaDAnCe-101 study Updated results from the phase 1 study of sonrotoclax (BGB-11417), a novel BCL2 inhibitor, in combination with zanubrutinib for relapsed/refractory CLL/SLL demonstrate deep and durable responses Updated results of sonrotoclax + dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma: An all-oral treatment